China's National Medical Products Administration (NMPA) has cleared an IND application for a clinical trial of Shanghai Henlius Biotech Inc.'s HLX-60 for the treatment of solid tumors and lymphomas.
Akeso Inc. has received approval from China's National Medical Products Administration (NMPA) for a phase Ib/II trial of ivonescimab (AK-112) combined with drebuxelimab (AK-119) for the treatment of advanced solid tumors.
Innocare Pharma Ltd. has received IND approval from China's National Medical Products Administration (NMPA) to begin clinical trials of its B-cell lymphoma-2 (BCL2) inhibitor ICP-248.
China's National Medical Products Administration (NMPA) has cleared CSPC Pharmaceutical Group Limited to conduct clinical trials of TG-103 injection for the treatment of Alzheimer's disease and for the treatment of nonalcoholic steatohepatitis (NASH).
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has patented cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has disclosed pyrimidines or pyridines acting as adenosine receptor antagonists reported to be useful for the treatment of cancer.
Southern Marine Science and Engineering Guangdong Laboratory and Guangdong Medical University have disclosed peptides acting as angiotensin-converting enzyme (ACE) inhibitors reported to be useful for the treatment of hypertension.
RSS
